Status
Acquired by Shire on August 3, 2010
Funding Received
$191.2 Million in 2 Rounds from 8 Investors
Founded:
2006
Headquarters:
Turnhout
Description:
Movetis is focused on the development of drugs for the treatment of diseases in the gastrointestinal area.
Founders:
Staf Van Reet, Dirk Reyn
Categories:
Biotechnology
Website:
http://www.movetis.com

Detailed Description

Update

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company’s lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient’s refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Current Team (1)

Update

Past Team (1)

Update

Funding Rounds (2) - $191.2M

Update

Board Members and Advisors (1)

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    Veedijk 58 1004

    Turnhout, 2300

    BEL

Images (1)

Update
  • 71a8f1897527d54f2eb39d5f234b74b3